Intra-Cellular's schizophrenia drug meets main goal in late-stage trial (updated)

Intra-Cellular Therapies

05/11/2024 12:40

(Adds details paragraph 2 onwards)
       Nov 5 (Reuters) - Intra-Cellular Therapies  ITCI.O  said
on Tuesday its drug to prevent relapses in schizophrenia
patients met the main goal of a late-stage trial.
    Schizophrenia relapse is the return of symptoms after
partial recovery from the illness. It's a common characteristic
of schizophrenia, with up to 81.9% of people with the condition
experiencing a relapse within five years of diagnosis.
    The oral drug, lumateperone, showed a 63% reduction in risk
of relapse compared to a placebo.
        Lumateperone is also under development as an adjunctive
therapy for Major Depressive Disorder (MDD). The company plans
to submit a marketing application for the drug in MDD in the
fourth quarter of the year.
        Currently approved schizophrenia drugs include Vanda
Pharmaceuticals'  VNDA.O  Fanapt, AbbVie's  ABBV.N  Vraylar and
Bristol Myers Squibb's  BMY.N  Cobenfy. 
    Schizophrenia, which causes persistent delusions and
hallucinations, affects about 24 million people worldwide,
according to the World Health Organization.
        
  

 (Reporting by Christy Santhosh in Bengaluru; Editing by Savio
D'Souza and Tasim Zahid)
 ((Christy.Santhosh@thomsonreuters.com;))